Last updated 2026-07-20
Portfolio
0
in our dataset
Rounds participated
0
Rounds led
0
Rounds' value
—
total disclosed, rounds participated
Stages
—
About
Dr. Shmuel Cabilly is a scientist and inventor in the field of immunology, known for his breakthrough inventions related to recombinant antibody production, often referred to as the “Cabilly patents.” These patents have been foundational for the development of numerous drugs. He was also a co-founder and Chief Scientist of Ethrog Biotechnology, which was acquired by Invitrogen (now Thermo Fisher). Currently, Dr. Cabilly is an angel investor and serves on the boards of several high-technology companies in Israel.
Portfolio
No portfolio companies in this dataset yet.
Investment activity
1 portfolio exit on record.
Portfolio by sector
Health Tech & Life Sciences1
Q&A
- What is Shmuel Kabili's primary investment focus by sector?
- Shmuel Kabili has concentrated investments in the Health Tech & Life Sciences sector, with all recorded portfolio companies and exits falling within this category.
- Can you name a notable portfolio company for Shmuel Kabili?
- A notable portfolio company for Shmuel Kabili is RedHill Biopharma, which develops proprietary drugs for gastrointestinal and infectious diseases.
- What was a significant exit for Shmuel Kabili?
- Shmuel Kabili had a significant exit with RedHill Biopharma, which went public on NASDAQ in January 2012.
- What stage of funding does Shmuel Kabili typically participate in?
- Shmuel Kabili has participated in Seed stage funding rounds, as evidenced by an investment in November 2010.
- When was Shmuel Kabili's most recent investment activity?
- Shmuel Kabili's most recent recorded investment activity was in November 2010.